Lack of any Association of the CTLA-4 +49 G/A Polymorphism with Breast Cancer Risk in a North Indian Population

Minhas, S.; Bhalla, Sunita; Shokeen, Yogender; Jauhri, Mayank; Saxena, Renu; Verma, I. C.; Aggarwal, Shyam

doi:10.7314/apjcp.2014.15.5.2035

Cited by 14 publications

(7 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1B). However, some studies showed that lack of association between CTLA-4 polymorphisms and some types of cancer, including esophageal cancer in a Chinese population [57,58] and breast cancer in a North Indian population [59]. It is required to confirm the findings in large-scale and multi-populations studies.…”

Section: Ctla-4 Polymorphisms In Cancermentioning

confidence: 99%

Evolving Roles for Targeting CTLA-4 in Cancer Immunotherapy

Zhao

Yang

Huang

et al. 2018

Cell Physiol Biochem

148

View full text Add to dashboard Cite

Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) is a membrane glycoprotein expressed by activated effector T cells (Teffs) and participates in the repression of T cell proliferation, cell cycle progression and cytokine production. Currently, antibodies targeting CTLA-4, ipilimumab and tremelimumab are widely used as a therapeutic approach in a variety of human malignancies. However, their detailed mechanism remains unclear. Therefore, in this review, we focused specifically on recent findings concerning the role of CTLA-4 in immune response and also discussed clinical studies of targeting CTLA-4, alone or in combination with other therapies for the treatment of cancers. CTLA-4 blockade is used as a therapeutic approach for the treatment of cancer through competing with CD28-positive costimulation for binding to their shared B7 ligands or exhibiting direct inhibitory effect on signaling molecules in the cytoplasmic tail. At present, antibodies for targeting CTLA-4 or in combination with other therapies significantly reinforced the anti-tumor effect and improved the prognosis of malignant disease. In addition, severe adverse events of targeting CTLA-4 therapy could be a challenge for the development of this therapeutic strategy. This review may provide some new insights for clinical studies of targeting CTLA-4.

show abstract

Section: Ctla-4 Polymorphisms In Cancermentioning

confidence: 99%

Evolving Roles for Targeting CTLA-4 in Cancer Immunotherapy

Zhao

Yang

Huang

et al. 2018

Cell Physiol Biochem

148

View full text Add to dashboard Cite

show abstract

“…Numerous investigations have demonstrated that CTLA-4 genetic polymorphisms may have association with human breast cancer susceptibility (Erfani et al, 2006; Ghaderi et al, 2004; Li et al, 2012; Li et al, 2008; Minhas et al, 2014; Sun et al, 2008; Wang et al, 2007; Zhifu et al, 2015; Kong, 2010). The results showed that some of the polymorphisms such as rs733618 and rs4553808 may increase the breast cancer risk while other polymorphisms such as rs231775 and rs3087243 may reduce the risk of breast cancer.…”

Section: Introductionmentioning

confidence: 99%

CTLA-4 polymorphisms associate with breast cancer susceptibility in Asians: a meta-analysis

Dai

Tian

Wang

et al. 2017

PeerJ

View full text Add to dashboard Cite

Previous studies have investigated the association between cytotoxic T-lymphocyte antigen-4 (CTLA-4) polymorphisms and breast cancer susceptibility, but the results remained inconsistent. Therefore, we evaluated the relationship between four common CTLA-4 polymorphisms and breast cancer risk by a meta-analysis, aiming to derive a comprehensive and precise conclusion. We searched EMBASE, Pubmed, Web of Science, CNKI, and Wanfang databases until July 18th, 2016. Finally, ten eligible studies involving 4,544 breast cancer patients and 4,515 cancer-free controls were included; all these studies were from Asia. Odds ratio (OR) and 95% confidence interval (CI) were used to evaluate the breast cancer risk in five genetic models. The results indicated that the CTLA-4 +49A>G (rs231775) polymorphism had a significant association with decreased breast cancer risk in allelic, homozygous, dominant and recessive models. Also, the +6230G>A (rs3087243) polymorphism reduced breast cancer risk especially in the Chinese population under homozygous and recessive models. In contrast, the −1661A>G (rs4553808) polymorphism increased breast cancer risk in allelic, heterozygous and dominant models, whereas −1722 T>C (rs733618) did not relate to breast cancer risk. In conclusion, CTLA-4 polymorphisms significantly associate with breast cancer susceptibility in Asian populations, and different gene loci may have different effects on breast cancer development. Further large-scale studies including multi-racial populations are required to confirm our findings.

show abstract

“…CTLA-4 gene is located in several immune regulatory gene areas of human chromosome 2q33 to 2q37 and contains many single nucleotide polymorphisms in the CTLA-4 gene. Among these polymorphisms, CTLA-4 A49G was widely studied and have been reported to be associated with the susceptibility of diverse human diseases (Cozar et al, 2007;Wang et al, 2007;Dilmec et al, 2008;Minhas et al, 2014). Some studies have reported the association between CTLA-4 A49G polymorphism and colorectal cancer; however, the results are conflicting (Solerio et al, 2005;Hadinia et al, 2007;Qi et al, 2010).…”

Section: Introductionmentioning

confidence: 99%

The association of CTLA‐4 A49G polymorphism with colorectal cancer risk in a Chinese Han population

Wang

Zhao

2015

Int J Immunogenetics

View full text Add to dashboard Cite

Cytotoxic T-lymphocyte antigen-4 (CTLA-4) is expressed in T cells and plays an important role in the regulation of T cell. CTLA-4 has long been considered to be associated with various kinds of diseases. With the attempt to examine the association between CTLA-4 A49G polymorphism and colorectal cancer risk in a Chinese Han population, we employed TaqMan assay to genotype the CTLA-4 A49G polymorphism in 311 colorectal cancer cases and 389 cancer-free controls. We found evidence of the association between CTLA-4 A49G polymorphism and colorectal cancer risk (GG vs. AA: OR = 2.01, 95% CI = 1.29-3.07, P = 0.002; GA vs. AA: OR = 2.32, 95% CI = 1.53-3.57, P = 0.001; GA + GG vs. AA: OR = 2.16, 95% CI = 1.46-3.21, P = 0.001). Next, we performed a meta-analysis to comprehensively examine the association between CTLA-4 A49G polymorphism and colorectal cancer risk. We found a significant association between CTLA-4 A49G polymorphism and colorectal cancer risk among Asians, which is consistent with our result. However, we found no evidence for the association between CTLA-4 A49G polymorphism and colorectal cancer risk among Caucasians. In conclusion, we demonstrated that the CTLA-4 A49G polymorphism increased the susceptibility of colorectal cancer in Asian population.

show abstract

Lack of any Association of the CTLA-4 +49 G/A Polymorphism with Breast Cancer Risk in a North Indian Population

Cited by 14 publications

References 22 publications

Evolving Roles for Targeting CTLA-4 in Cancer Immunotherapy

Evolving Roles for Targeting CTLA-4 in Cancer Immunotherapy

CTLA-4 polymorphisms associate with breast cancer susceptibility in Asians: a meta-analysis

The association of CTLA‐4 A49G polymorphism with colorectal cancer risk in a Chinese Han population

Contact Info

Product

Resources

About